Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q3 2022 · 10-Q
Revenue$7.36M$7.36M−69.4% vs Q3 2021 Net Income-$23.95M-$23.95MN/M vs Q3 2021 EPS Diluted-$0.22-$0.22N/M vs Q3 2021 Operating Income-$14,676,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$28,096,000N/M Margins · derivedOperating margin-199.3%−151.3 pt vs Q3 2021
Net margin-325.2%−278.3 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end